|
|
|
|
Vol. 57, Issue 2, 243-251, February 2000
Cancer Therapy & Research Center, Institute for Drug Development,
San Antonio, Texas (B.V., J.M.W., D.D.V.H., R.M.W.); and Research
Triangle Institute, Research Triangle Park, North Carolina (G.M.,
M.C.W., M.E.W.).
7-Alkyl, 7-alkyl-10-hydroxy, 7-alkyl-10-methoxy, and
7-alkyl-10,11-methylenedioxy analogs of camptothecin have been
synthesized and evaluated for their ability to trap human DNA
topoisomerase I in cleavable complexes. The 7-alkyl chain lengths
varied linearly from methyl to butyl. The concentration required to
produce cleavable complexes with purified topoisomerase I in 50% of
the plasmid DNA (EC50) was reduced by 1 order of magnitude
by the introduction of a 10-methoxy or 7-alkyl group compared with
camptothecin. The EC50 values were reduced by 2 orders of
magnitude with a 10-hydroxy or 10,11-methylenedioxy moiety compared
with camptothecin. The steady-state EC50 concentrations for
all of the analogs tested were slightly dependent on substitution at
the 7-position, but this dependence was least with the 10-methoxy
series. The kinetics of the reversibility of the complexes formed with
all analogs was only slightly influenced by the length of the
7-substitution, with the trend that ethyl or greater lengths led to
slightly reduced rate constants for cleavable complex reversal. These
results were also observed for DNA-protein cross-link formation by the
analogs in isolated CEM cell nuclei. Our data indicate that in vitro
cleavable complex stability, as determined by the apparent rate
constants for complex dissociation, does not reflect the in vitro
biological activity of these camptothecin analogs. However, complex
stability in vivo may be important for the antitumor activity of the compounds.
This article has been cited by other articles:
![]() |
D. J. Baker, G. Wuenschell, L. Xia, J. Termini, S. E. Bates, A. D. Riggs, and T. R. O'Connor Nucleotide Excision Repair Eliminates Unique DNA-Protein Cross-links from Mammalian Cells J. Biol. Chem., August 3, 2007; 282(31): 22592 - 22604. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huang, H. Gao, Y. Chen, H. Zhu, Y. Cai, X. Zhang, Z. Miao, H. Jiang, J. Zhang, H. Shen, et al. Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles In vitro and In vivo Clin. Cancer Res., February 15, 2007; 13(4): 1298 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer Ther., April 1, 2006; 5(4): 962 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Wadkins, D. Bearss, G. Manikumar, M. C. Wani, M. E. Wall, and D. D. Von Hoff Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I Cancer Res., September 15, 2004; 64(18): 6679 - 6683. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Loos, J. Verweij, D. F. S. Kehrer, P. de Bruijn, F. M. H. de Groot, M. Hamilton, K. Nooter, G. Stoter, and A. Sparreboom Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20(S)-Camptothecin, a Photodegradant of Lurtotecan Clin. Cancer Res., March 1, 2002; 8(3): 856 - 862. [Abstract] [Full Text] [PDF] |
||||